Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Brainstem Glioma: early-phase trial registry

1 of 6 indexed Brainstem Glioma trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,866 of 28,707 conditions by registered trial count.

6 US clinical trials · 1 currently recruiting · #2,866 of 28,707 conditions by registered trial count

Brainstem Glioma: 6 US clinical trials tracked, 1 recruiting.

Brainstem Glioma is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Y-mAbs Therapeutics, running 1 of these trials.

Enrollment posture brief

Registry condition brainstem-glioma

OPEN 1 | RECR 17% | LATE 0 | EARLY 5 | RANK #2866 | SPON 1

Nearest open-share peer: Acute Renal Failure (17% recruiting · 6 trials)

Acute Hypoxemic Respiratory 66.7%Abdominal Aortic Aneurysms50%Acupuncture50%Acute Lymphoblastic Leukemia50%Brainstem Glioma (this)17%
Open-enrollment share among volume-matched conditions near Brainstem Glioma

Brainstem Glioma lists 1 open slots (17% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Brainstem Glioma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Brainstem Glioma is recruiting below its size-band peers.

    1 of 6 indexed trials (16.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Brainstem Glioma research.

    Y-mAbs Therapeutics accounts for 1 of 6 trials (16.7%). 6 distinct sponsors appear on at least one study for this condition label.

  3. Most Brainstem Glioma trials plan to enrol fewer than 100 people.

    Median target enrolment is 50 among the 6 trials that report a genuine target (sentinel values excluded). 4 of those (66.7%) plan for fewer than 100 participants.

  4. Brainstem Glioma research is mostly interventional.

    5 interventional and 1 observational studies make up this index (83.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 14Phase 21

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 1

Named interventions

Most-linked intervention names on Brainstem Glioma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Radioactive iodine-labeled monoclonal antibody omburtamab Drug
1 trials
AZD8055 Drug
1 trials
therapeutic allogeneic lymphocytes Biological
1 trials
Methionine Drug
1 trials
aldesleukin Biological
1 trials
positron emission tomography Procedure
1 trials
External Beam Radiotherapy Radiation
1 trials
ribociclib Drug
1 trials

US sites by state

Facility locations filed on Brainstem Glioma trials. A trial with sites in several states counts in each.

Washington 1 trials
Texas 1 trials
Tennessee 1 trials
Ohio 1 trials
New York 1 trials
North Carolina 1 trials
Maryland 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Brainstem Glioma page

6 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Brainstem Glioma condition card totals 6 registered trials; most-linked intervention Radioactive iodine-labeled monoclonal antibody omburtamab; top US site state District of Columbia. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.